phrykt

Mustang Bio, Inc. (MBIO): who owns it and who trades it

As of Nov 16, 2026, MBIO insiders reported 2 open-market sales worth $241 and 1 purchase worth $237 in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Herskowitz (Director), with $237. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Mustang Bio

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, MBIO insiders reported $237 of open-market purchases and $241 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$237
1 trades, 1 people
Sales, 12 months
$241
2 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 30, 2025
Filed Dec 30, 2025

Purchases and sales by month

$241$241DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 30, 2025Neil HerskowitzDirectorSale247$0.96$237Form 4
Dec 30, 2025Adam J. ChillDirectorSale4$0.95$4Form 4
Dec 30, 2025David JinDirectorPurchase247$0.96$237Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Neil HerskowitzDirector–$237Dec 30, 2025
David JinDirector$237–Dec 30, 2025
Adam J. ChillDirector–$4Dec 30, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MBIO short interest

70,238 MBIO shares are sold short. Over the last 12 reports the number of shares short went up 31%.

As of Oct 30, 2026, 70,238 MBIO shares were sold short, up 19.3% from the report before. At the average daily volume of 25,449 shares, buying them all back would take about 2.8 trading days (days to cover).

Shares short

70,238May 15Oct 30165,336

Days to cover

2.8May 15Oct 303.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202670,238–+19%25,4492.8
Oct 15, 202658,855–+12%54,4651.1
Sep 30, 202652,680–-10%31,2051.7
Sep 15, 202658,509–+6%23,4982.5
Aug 31, 202655,039–+5%15,5053.5
Aug 14, 202652,568–-5%36,8291.4
Jul 31, 202655,145–-9%28,7311.9
Jul 15, 202660,867–-41%41,9801.4
Jun 30, 2026102,440–-32%49,5762.1
Jun 15, 2026150,627–+176%553,9981.0
May 29, 202654,570–+2%45,5451.2
May 15, 202653,594–-26%40,8471.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Mustang Bio company events

Mustang Bio filed 3 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Oct 15, 2026.

  1. Oct 15, 2026AnnouncementAs previously disclosed, on April 15, 2026, Mustang Bio, Inc. received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the bid price of the Company’s common stock, par value $0.0001 per share, had closed below $1.00 per share for 30… Filing
  2. Apr 17, 2026ListingNotice of Delisting of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Filing
  3. Dec 23, 2025AnnouncementAs previously disclosed, Mustang Bio, Inc. previously entered into that certain License Agreement with Fred Hutchinson Cancer Center, dated as of May 17, 2017 (as amended, the “ CD20 License Agreement ”), under which the Company developed its CD20 CAR-T program. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Mustang Bio financials

Famous investors that hold MBIO

1 of the 50 well-known investors we track reported holding MBIO in their latest 13F filing. The largest position is Ken Griffin's, worth $32.4K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202670,062$32.4K0.0%+18%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Mustang Bio, Inc. (MBIO) stock

Are MBIO insiders buying or selling?

In the last 12 months, MBIO insiders reported 1 open-market purchase worth $237 and 2 sales worth $241. The latest trade was on Dec 30, 2025. See every trade.

What is the short interest in MBIO?

As of Oct 30, 2026, 70,238 MBIO shares were sold short, up 19.3% from the report before. At the average daily volume of 25,449 shares, buying them all back would take about 2.8 trading days (days to cover). See the history.

Which famous investors hold MBIO?

1 of the 50 well-known investors we track reported MBIO in their latest 13F filing, including Ken Griffin. The largest position is worth $32.4K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.